Table 4. Adjusted mean change from baseline to week 24 in SF-36 dimensions in patients with a high drinking risk level (MMRM, target efficacy population).

Short-Form health survey-36 (SF -36) Dimensions		Baseline		Change from Baseline to Week12		Difference to Placebo			Change from Baseline to Week 24		Difference to Placebo
		N	Mean ± SD	N	Mean ± SE	Mean ± SE	95% CI	p-value	N	Mean ± SE	Mean ± SE	95% CI	p-value
Bodily Pain	Placebo	319	49.16 ± 10.66	279	0.73 ± 0.67				226	1.47 ± 0.70
	Nalmefene	316	49.85 ± 10.63	283	2.46 ± 0.66	1.73 ± 0.74	[0.28; 3.17]	0.0195	189	3.90 ± 0.72	2.43 ± 0.82	[0.82; 4.05]	0.0032
General Health	Placebo	318	43.84 ± 9.56	277	0.85 ± 0.56				224	1.46 ± 0.61
	Nalmefene	318	44.71 ± 9.53	283	2.47 ± 0.54	1.62 ± 0.60	[0.45; 2.79]	0.0066	189	3.82 ± 0.62	2.36 ± 0.71	[0.96; 3.76]	0.0010
Mental Health	Placebo	319	41.97 ± 11.35	280	2.01 ± 0.66				226	1.82 ± 0.70
	Nalmefene	316	41.66 ± 11.34	283	2.01 ± 0.66	1.61 ± 0.71	[0.21; 3.01]	0.0247	188	4.99 ± 0.72	3.17 ± 0.83	[1.54; 4.79]	0.0001
Physical Functioning	Placebo	317	50.95 ± 6.84	277	0.50 ± 0.43				223	1.03 ± 0.43
	Nalmefene	318	51.01 ± 7.01	281	1.59 ± 0.42	1.09 ± 0.47	[0.16; 2.02]	0.0216	187	2.24 ± 0.44	1.21 ± 0.49	[0.24; 2.18]	0.0142
Role Emotional	Placebo	316	42.36 ± 11.40	274	0.67 ± 0.71				221	2.33 ± 0.75
	Nalmefene	317	42.46 ± 11.46	280	3.25 ± 0.69	2.58 ± 0.77	[1.06; 4.10]	0.0009	188	4.66 ± 0.77	2.33 ± 0.89	[0.58; 4.08]	0.0093
Role Physical	Placebo	316	45.51 ± 9.2	273	0.94 ± 0.56				222	2.00 ± 0.60
	Nalmefene	317	45.89 ± 9.34	281	2.64 ± 0.54	1.71 ± 0.60	[0.52; 2.89]	0.0048	188	3.36 ± 0.61	1.36 ± 0.71	[-0.04; 2.75]	0.0561
Social Functioning	Placebo	319	43.33 ± 11.95	280	3.93 ± 0.61				226	3.20 ± 0.67
	Nalmefene	317	44.32 ± 10.62	284	2.09 ± 0.63	1.84 ± 0.69	[0.49; 3.19]	0.0078	189	5.36 ± 0.68	2.17 ± 0.79	[0.62; 3.71]	0.0061
Vitality	Placebo	319	47.04 ± 10.16	280	1.96 ± 0.60				226	1.97 ± 0.65
	Nalmefene	319	47.48 ± 9.56	283	3.55 ± 0.58	1.59 ± 0.64	[0.33; 2.86]	0.0135	188	4.30 ± 0.66	2.34 ± 0.77	[0.83; 3.84]	0.0024

MMRM: mixed model repeated measures.